Stockwinners Market Radar for September 22, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:48 EDT Oracle wins litigation against OFCCP - Oracle announced that the Department of Labor Administration Law Judge ruled across the board in Oracle's favor and found no evidence whatsoever of discrimination at Oracle. Among Judge Clark's findings: Oracle did not engage in intentional compensation discrimination at its headquarters facility during the relevant time period against female employees in the Product Development, Information Technology, and Support job functions. Oracle did not have a policy or practice at its headquarters facility during the relevant time period of relying on prior pay in salary setting and OFCCP did not show a disparate impact attributable to such a policy on female employees in the Product Development, Information Technology, and Support job functions; or on Asian and African American employees in the Product Development job function. Oracle did not engage in assignment, job classification, or steering discrimination at its headquarters facility during the relevant time period against female employees in the Product Development, Information Technology, and Support job functions; or against Asian and African American employees in the Product Development job function.

18:42 EDT Tesla CEO says very confident can make a $25K electric car in 3 years

18:14 EDT Tesla aims for 100GWh by 2022 and 3TWh by 2030 - CEO Musk says there's a good chance of achieving 3TWh goal before 2030. Says Silicone can store 9-times more than lithium and graphite. Comments taken from investor presentation at Tesla's "Battery Day."

18:01 EDT Norbord announces automatic share purchase plan - Norbord reported that it has entered into an automatic share purchase plan, or ASPP, with a broker in order to facilitate repurchases of Norbord's common shares under its previously announced normal course issuer bid. The Company previously announced that it had received approval from the Toronto Stock Exchange to purchase up to 4,083,429 of its common shares, representing approximately 5% of the Company's issued and outstanding common shares, during the 12-month period commencing November 5, 2019 and terminating November 4, 2020. Such purchases made pursuant to the NCIB are made on the open market by Norbord through the facilities of the TSX, the New York Stock Exchange or Canadian or US alternative trading systems, if eligible, in accordance with the requirements of the TSX and applicable securities laws.

17:55 EDT Tesla aims to cut cost of battery KWh in half - Comments taken from investor presentation at Battery Day.

17:46 EDT Nike extends afterhours gains after upping first half, FY21 revenue view - Shares of Nike are up over 11% at $130 per share after the company guided FY21's first half revenue flat and FY21 revenue up high single to low double-digits. At its last earnings conference call on June 25th, Nike guided first half revenue "below prior year's levels" and FY21 revenue "flat to up" from FY20.

17:30 EDT KB Home sees FY21 housing revenue $5.1B-$5.5B - Sees FY21 community count up mid- to high-single digit range. Says temporary pause in land development caused only 19 communities to be opened in Q3. Says 30 community opening planned for Q4. Sees 135 new communities opening in FY21. Says California wildfires have not had a material impact to this date. Says net orders up 32% for first three weeks of September.

17:27 EDT Stitch Fix has confidence in accelerating growth in 2H21 - Says investing in distribution centers. Sees loss of March-May clients will roll forward and impact numbers in first half of 2021. Says has confidence in accelerating growth in 2H of 2021. Says will be flexible in how company uses marketing dollars in 2021. Says plans to invest higher level of capex in 2021 to expand capacity.

17:16 EDT Nike CEO says Q1 showed that deepening connection w/ consumers matters - Says Nike Digital already meeting mix growth of 30% 3 years ahead of schedule and is expected to grow from here. Says Digital accelerated even as store doors reopened. Comments taken from Q1 earnings conference call.

17:06 EDT Genmab commences arbitration of two matters under license agreement with Janssen - Genmab (GMAB) announced that it has commenced binding arbitration of two matters arising under its license agreement with Janssen Biotech (JNJ) relating to daratumumab. Under the license agreement, Genmab is, among other things, entitled to royalties from Janssen on sales of daratumumab. The arbitration first is to settle whether Genmab is required to share in Janssen's royalty payments to Halozyme Therapeutics, Inc. for the Halozyme enzyme technology used in the subcutaneous formulation of daratumumab. The royalties Janssen pays to Halozyme represent a mid-single digit percentage rate of subcutaneous daratumumab sales. Janssen has started reducing its royalty payments to Genmab by what it claims to be Genmab's share of Janssen's royalty payments to Halozyme for the second quarter of 2020. The arbitration is also to settle whether Janssen's obligation to pay royalties on sales of licensed product extends, in each applicable country, until the expiration or invalidation of the last-to-expire relevant Genmab-owned patent or the last-to-expire relevant Janssen-owned patent covering the product, as further defined and described in the license agreement. The relevant Genmab-owned issued U.S., European and Japanese patents will expire in the late 2020s and early 2030s. The relevant Janssen-owned issued patents and patent applications (if granted) covering the subcutaneous formulation of daratumumab would expire in the mid-2030s. Under the agreement, the arbitration will be conducted in New York pursuant to the rules of the CPR Institute for Dispute Resolution for Non-Administered Arbitration before a panel of three arbitrators. While Genmab intends to vigorously protect its rights under the agreement, the outcome of any arbitration proceeding, as well as its duration, is inherently uncertain. The arbitration will be confidential, subject to the parties' disclosure obligations under applicable law. Other than pursuant to these obligations, Genmab does not intend to comment or provide additional information regarding the arbitration until an order on the merits or other material order is issued in the arbitration or the arbitration is otherwise concluded. While the arbitration is pending, Genmab's collaborations with Janssen on daratumumab and HexaBody-CD38 will continue. Based on currently available information, Genmab does not expect these matters to materially affect its 2020 financial guidance.

16:48 EDT Banner Corp. chief credit officer Richard Barton to retire, Jill Rice to succeed - Banner Bank executive announced the retirement of Richard Barton, executive VP and chief credit officer, effective October 31. Following Barton's retirement, Jill Rice, currently executive VP and senior credit officer, will assume the role of chief credit officer. Barton joined Banner Bank as chief credit officer in 2002,] and retired with more than 48 years of experience in the banking industry. Rice has been a leader in the credit policy division since joining the Bank in 2002, first as a regional credit risk manager, then as senior credit officer.

16:40 EDT Scorpio Bulkers announces purchase of 50K share by Scorpio Services Holding - Scorpio Bulkers announced that Scorpio Services Holding Limited, a related party, has purchased 50,000 common shares of the company at an average price of $12.04 per share in the open market. The company currently has 12,386,880 common shares outstanding, of which SSH and its affiliates own 2,647,751 or 21.38%.

16:33 EDT Entercom Chairman Field buys 248,071 shares of company stock - Entercom Chairman David Field purchased 248,071 shares of stock at $1.42 per share between September 18 and September 22 for $1.42 per shar for a total transaction value of $353,104.

16:31 EDT Beazer Homes says net new orders for Q4 up 37% y/y - Ahead of an upcoming investor conference, Beazer Homes announced that, based on preliminary operating results, net new orders for the first two months of its fiscal fourth quarter were up 37% year-over-year with a 26% increase in July and a 48% increase in August. This performance was primarily related to a higher pace, as sales per community per month rose to 4.4 from 3.0 in the previous year. "We are very pleased with our results through the first two months of our fourth quarter," said Allan P. Merrill, Chairman and CEO of Beazer Homes. "Broad, resilient demand across all our markets supported by low rates and a reassessment of housing needs drove substantial sales momentum and gives us confidence as we close out 2020 and look forward to fiscal 2021." The company expects to report its full fourth quarter 2020 results in November and is not updating any additional guidance at this time.

16:31 EDT Magnite names Katie Evans as COO - Magnite announced that Katie Evans has been named Chief Operating Officer of the company. In this newly created role, Katie will be responsible for scaling Magnite's global service operations and overseeing the company's client operations, technical operations and business intelligence teams. Katie formerly held the role of GM of CTV at Magnite. Prior to the formation of Magnite from the merger of Rubicon Project and Telaria, Katie was the Chief Operating Officer at Telaria.

16:26 EDT WWE director sells 57.6K shares of common stock - In a regulatory filing, WWE disclosed that its Chief Brand Officer Stephanie Levesque sold 57.6K shares of common stock on September 21st in a total transaction size of $2.26M. The holding represents about 43% of director's total owned.

16:21 EDT People's United to sell People's United Insurance Agency to AssuredPartners - People's United Bank,a subsidiary of People's United Financial announced that it has entered into a definitive agreement to sell People's United Insurance Agency to AssuredPartners. The transaction is expected to close in the fourth quarter of 2020, subject to customary closing conditions.

16:17 EDT Kratos Defense collaborates with Microsoft to launch Azure Orbital - Kratos Defense (KTOS) announced that it has joined with Microsoft (MSFT) to enable the launch of Microsoft Azure Orbital, a platform that provides Ground Station-as-a-Service, or GSaaS, to the satellite industry. Azure Orbital is Microsoft's managed service designed to deal with the growing flood of data from earth observation, or EO, and Internet of Things, or IoT, applications. The managed service lets satellite operators communicate to, control their satellites, process data and scale operations directly in Azure without the need to build or manage their own costly ground stations. Azure Orbital is powered by Microsoft's Ground-Station-as-a-Service Platform, or GSaaP, that includes virtualized infrastructure, orchestration and monitoring capabilities. Kratos' OpenSpace products are built into the underlying cloud architecture of Azure Orbital beginning with Kratos' OpenSpace Digitizer that converts the RF signal from the antenna into network-ready IP packets that are transported in a digital stream reliably and accurately by an OpenSpace virtual network function, or VNF. Orbital customers can then choose additional OpenSpace VNFs available in the Azure Marketplace for receiving and recording their signals. The health and status of the physical gateway-based devices and cloud-based VNFs can be monitored in a unified view with Kratos' OpenSpace OpsCenter Network Management Application.

16:17 EDT KB Home says demand beyond Q3 'remains strong' - KB Home states: "The company is encouraged by the resilience of the housing market and the significant increase in demand over the past several months. Subsequent to the end of the third quarter, demand remains strong, with the company's net orders for the first three weeks of September 2020 up 32% from the corresponding period of 2019, and the cancellation rate for the period improving to 12% from 17%. While the company limited its land investments during the second quarter and most of the third quarter to preserve cash and liquidity due to the uncertainty surrounding the COVID-19 pandemic, given the sustained strong housing demand, it has resumed land acquisition and development activities to bolster its lot pipeline and support community growth in the future. Although the trajectory and strength of the current recovery remains uncertain, and it could be slowed or reversed by a number of factors, including a possible widespread resurgence in COVID-19 infections combined with the seasonal flu, the company believes it is well positioned to operate effectively through the present environment."

16:13 EDT KB Home CEO says well positioned to expand scale in 2021 - CEO Jeffrey Mezger says: "As we look ahead to 2021, assuming market conditions remain favorable, we believe we are well positioned to expand our scale, and, with a leaner and more efficient operation, we anticipate accelerating our profitable growth next year, as we remain focused on generating higher returns."

16:11 EDT Stitch Fix reports Q4 active clients of 3.5M, up 9% year-over-year - Stitch Fix president Elizabeth Spaulding added, "We're particularly excited by the momentum of our direct buy offering. It's still early days, but the ability to shop personalized items and outfits in our feed-based experience is clearly resonating with our clients. Our styling algorithms combined with input from our talented stylists, and the network effects of nearly 10 years of shopping data are enabling clients to now shop via direct buy without ever having purchased something from us in the past. Encouraged by its early success, we plan to expand the offering to give existing clients more reasons to engage with us, and give new-to-Stitch Fix customers the opportunity to experience the magic of online personal styling through direct buy."

16:07 EDT Fuel Tech announces listing transfer to Nasdaq Capital Market - Fuel Tech announced that on September 22, 2020, the NASDAQ Stock Market approved the company's application to transfer its listing from NASDAQ's Global Select tier to the Capital Market tier. In connection with the transfer to the Capital Market tier, NASDAQ also granted the company an additional 180 calendar day grace period to regain compliance with the minimum bid requirement of NASDAQ Marketplace Rule 5450(a)(1) for continued listing. As previously reported, the company was notified by NASDAQ on January 7, 2020 that the bid price for its Common Stock was not in compliance with the Rule. At that time, NASDAQ gave the company 180 calendar days to regain compliance; this was subsequently extended to September 18, 2020. The company has until March 17, 2021, to demonstrate compliance with the minimum bid price requirement for continued listing. The company will regain compliance with the Rule if at any time before March 17, 2021, the bid price for the company's Common Stock closes at or above $1.00 per share for a minimum of 10 consecutive business days.

16:06 EDT Rockwell Automation applies to no longer be reporting issuer in Canada - Rockwell Automation announced that it has voluntarily applied to the Ontario Securities Commission for an order that it cease to be a reporting issuer in Ontario. Rockwell Automation is not a reporting issuer in any other jurisdiction in Canada. Rockwell Automation became a reporting issuer in Ontario in connection with the previous listing of its common stock on the Toronto Stock Exchange, from which it voluntarily delisted in 1995 due to low trading activity. Rockwell Automation is applying to cease to be a reporting issuer as its common stock has not been listed on any Canadian stock exchange for 25 years.

16:06 EDT United Insurance sees Q3 pre-tax catastrophe losses $135M - United Insurance Holdings Corp. announced estimated current year catastrophe losses incurred during the third quarter ending September 30, 2020 of approximately $135 million before income taxes, net of expected reinsurance recoveries. The company's third quarter catastrophe losses included claims from six new named windstorms and other non-named windstorm catastrophe events.

15:11 EDT Notre Dame football game postponed after seven positive COVID tests - A total of 94 COVID-19 tests were administered to Notre Dame Football student-athletes on Monday. Of those 94, there were seven positive tests, according to University Physician Dr. Matt Leiszler. Those seven student-athletes are in isolation and their close contacts have been/are being identified. In consultation with the St. Joseph County Department of Health, the Notre Dame Football program has decided to pause all football-related activities until further testing is completed. Combined with last week's testing results, a total of 13 players are currently in isolation, with 10 in quarantine. The ACC and Wake Forest have been notified, and the process of rescheduling the game originally slated for Sept. 26 is underway. Publicly traded companies in the sports betting space include Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (PDYPY), Gan Limited (GAN), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn National (PENN), William Hill (WIMHY) and Wynn Resorts (WYNN).Reference Link

15:05 EDT UC announces selection for trial of Aerpio COVID-19 drug candidate - Researchers at the University of Cincinnati and UC Health will host a Phase 2 clinical trial to examine the effects of a drug that targets blood vessel inflammation and injury in patients with COVID-19, the school announced. They will study the effects of razuprotafib, an investigational drug that activates a key pathway for stabilizing blood vessels in the lung and other organs in patients with moderate to severe cases of the respiratory illness caused by the novel coronavirus SARS-CoV-2. The drug may prevent and treat respiratory distress in COVID-19 patients. The Phase 2 clinical trial will assess safety, tolerability and efficacy of razuprotafib. UC is one of up to 20 sites across the United States selected for a randomized, double-blind and placebo-controlled study coordinated by Aerpio Pharmaceuticals. As part of that trial, which is designed as a parallel-group, dose escalation and proof-of-concept study, razuprotafib will be administered three times daily for a seven-day period to hospitalized patients. The trial may enroll approximately 180 patients nationwide. Reference Link

14:58 EDT Nikola founder Milton appears to have deleted Twitter account - When visiting the page for the former Twitter account of Trevor Milton, the founder and former executive chairman of Nikola, Twitter indicates that the account @nikolatrevor "doesn't exist." Prior to his recently announced resignation as executive chairman of the company, Milton was very active on Twitter. Reference Link

14:33 EDT Sorrento Therapeutics releases results of Phase 1B trial of Resiniferatoxin - Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced the public release of the results of its' multicenter, open-label, Phase 1b Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for the Treatment of Intractable Cancer Pain, at the 14th Annual Pain Therapeutics Summit held virtually from September 21 to 22, 2020. Data was presented by Srdjan Nedeljkovic, MD, Associate Professor of Anesthesia, Harvard Medical School/Brigham & Women's Hospital. This multicenter, open-label study enrolled 17 adults with intractable moderate to severe cancer pain. Subjects were treated with a one-time epidural administration of RTX at escalating dose level cohorts, ranging from 0.4 microgram to 25 microgram in 3 ml saline, in seven cohorts. The first participant in each cohort served as the "Sentinel" subject. The first two dosing cohorts each included one subject. Subsequent cohorts proceeded with three subjects each. Enrollment of dose escalation cohorts has completed, with 17 subjects receiving RTX. 65% were women and 35% were men. The median age was 58 years. The baseline numerical pain rating scale average score was a mean of 6.8, and the baseline NPRS worst score was a mean of 7.9. No dose-limiting toxicities were reported. "We are extremely encouraged by the results of this initial study. Even in patients with high levels of pain, RTX given via an epidural injection has been found to reduce pain intensity without having any long-term adverse safety consequences. The patient population had intractable pain that did not respond to other standard therapeutic approaches, including opioids. The addition of RTX to the management of patients with intractable advanced-stage cancer pain offers the prospect of reducing suffering and improving quality of life for this underserved patient population," said Associate Professor of Anesthesia, Srdjan Nedeljkovic, M.D. from the Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital at Harvard Medical School.

13:36 EDT Nikola CFO says 'we've heard' when asked about SEC, DOJ probes - Nikola CFO Kim Brady, when speaking earlier at Evercore ISI's virtual conference, says "we've heard" when he was asked about the potential investigations into the company by both the Securities and Exchange Commission and Department of Justice. Brady added that Nikola reached out to the SEC following the short report from Hindenburg Research.

13:20 EDT Nikola CFO likens production of trucks to Apple's iPhone - Nikola (NKLA) CFO Kim Brady, while speaking earlier at Evercore ISI's virtual conference, likened the company's truck production to Apple (AAPL) and the iPhone. Brady said Apple doesn't manufacture the components of the iPhone, but it designs and controls the functions. He views Nikola similarly when it comes to its electric trucks.

13:16 EDT Nikola says most components will be manufactured by third party - Nikola CFO Kim Brady spoke earlier at Evercore ISI's virtual conference.

13:11 EDT Nikola CFO says 'nothing has changed' with partnerships in past few weeks - Nikola CFO Kim Brady spoke earlier at Evercore ISI's virtual conference.

13:00 EDT Yandex confirms discussions with Tinkoff Group - Yandex confirmed that it is in discussions with TCS Group Holding regarding a possible offer by Yandex for 100% of the share capital of Tinkoff. The parties have come to an agreement in principle on a transaction that would consist of cash and share consideration worth approximately $5.48B or $27.64 per Tinkoff share, which, based on the closing price of Yandex shares on September 21, 2020, would represent a premium of approximately: 8.0% to the closing price per Tinkoff GDR of $25.60 on September 21, 2020; 10.4% to the volume weighted average closing price per Tinkoff GDR of $25.04 for the one-month period ended on September 21, 2020; and 16.9% to the volume weighted average closing price per Tinkoff GDR of $23.65 for the three-month period ended on September 21, 2020. The final terms are subject to the satisfactory completion of due diligence and agreement on definitive documentation, including agreement regarding conditions to closing. There can be no certainty that any firm offer will be made for Tinkoff, nor as to the final terms on which any firm offer might be made. The current intention of Yandex and Tinkoff is for the Potential Transaction to be implemented by means of a scheme of arrangement of Tinkoff under Cyprus law. The Proposed Transaction would be subject to the approval of Yandex's Class A shareholders and General Meeting of shareholders. If the Potential Transaction proceeds, Yandex will provide notice of its shareholders meetings and accompanying documentation in due course.

12:41 EDT Apple reports issues with several services, including App Store, Apple Music - Apple said that some users are experiencing problems while accessing a handful of services, including the App Store, Apple Music, Apple TV Channels, Apple TV+, the iTunes store, and the Mac App Store. The company noted that issues with Apple Business Manager and Apple School Manager have been resolved. Reference Link

12:25 EDT Canada exercises increased option for 20M doses of Moderna COVID-19 vaccine - Moderna announced the Canadian Government has increased its confirmed order commitment to 20M doses of Moderna's vaccine candidate against COVID-19, mRNA-1273. This updated agreement comes as Moderna's Phase 3 COVE study has enrolled more than 75% of its participants, 11,879 of whom have received their second vaccination as of September 18, 2020. To provide additional transparency in the context of the pandemic, the company also made the complete, unredacted protocol for the Phase 3 trial of mRNA-1273 available on Thursday, September 17. "We appreciate the confidence in Moderna's mRNA platform and the progress we are making with mRNA-1273, as demonstrated by the increased order from the Canadian government today," said Stephane Bancel, Moderna's CEO. "This support, along with that of our stakeholders, drives us forward as we scale-up our global manufacturing and distribution network." Moderna remains on track to be able to deliver up to 56M doses of its COVID-19 vaccine to help protect Canadians beginning in 2021. The Canadian vaccine supply will be sourced from Moderna's European production capacity with its strategic manufacturing partner Lonza of Switzerland, and ROVI of Spain for fill-finish services.

12:17 EDT IsZo Capital comments on Nam Tai's appointment of Kaisa affiliates - IsZo Capital Management LP, a significant long-term shareholder of Nam Tai Property with beneficial ownership of approximately 10% of the Company's outstanding shares, today commented on the Company's troubling decision to appoint three individuals with documented ties to Kaisa Group Holdings Limited to the roles of Executive Chairman, CEO and CFO. IsZo recently announced that it delivered to Nam Tai verified requests to convene a meeting of Nam Tai shareholders from holders of more than 40% of the company's outstanding shares. The Special Meeting will provide shareholders an opportunity to reconstitute the Company's Board of Directors by removing a majority of the incumbent directors and installing six individuals: Michael Cricenti, Cindy Chen Delano, Bo Hu, Louis Leung, Paula J. Poskon and Jeffrey Tuder. Brian Sheehy, IsZo's founder and managing partner, commented: "Shareholders should be outraged that Nam Tai has exacerbated its dismal corporate governance and laid the groundwork for more conflicts of interest by appointing three Kaisa-affiliated individuals - Dr. Lai Ling Tam, Jiabiao Wang and Wai Hang Wan - to the roles of Executive Chairman, CEO and CFO. This insulting and tone deaf response to shareholders' overwhelming demand for the Special Meeting only validates our view that Kaisa insiders must be removed from the Board and replaced by our highly-qualified, integrity-rich director candidates. The last time Kaisa appointed its allies to key management positions at Nam Tai it fueled hundreds of millions of dollars in value destruction and led to the widespread marginalization of non-insider shareholders. Rather than continuing to brazenly ignore the critical mass of shareholders seeking authentic and credible leadership changes, Nam Tai must comply with investors' formal legal requests and promptly schedule the Special Meeting."

12:11 EDT Intel appoints Saf Yeboah-Amankwah as Chief Strategy Officer - Intel announced the appointment of Safroadu Yeboah-Amankwah as senior vice president and chief strategy officer, effective Nov. 1. Yeboah-Amankwah will be responsible for the global strategy office, including Intel Capital, and will work with the executive team on developing and driving growth-oriented strategies. Yeboah-Amankwah will report to CEO Bob Swan. Yeboah-Amankwah joins Intel from McKinsey & Company, where he was most recently a senior partner and global head of the Transformation Practice for the Telecom, Media and Technology practice.

12:00 EDT Lithium Americas falls -10.2% - Lithium Americas is down -10.2%, or -$1.00 to $8.83.

12:00 EDT Accel Entertainment falls -13.1% - Accel Entertainment is down -13.1%, or -$1.84 to $12.23.

12:00 EDT GameStop rises 20.5% - GameStop is up 20.5%, or $1.79 to $10.54.

11:48 EDT Izea reports 'significant contract' for marketing of alcoholic beverages - Izea Worldwide announced that it has secured a "mid six-figure contract with a leading spirits manufacturer, a significant expansion upon the first contract awarded to Izea earlier this year." In addition to this "significant" contract, Izea said it has been awarded multiple contracts with other manufacturers and marketers of alcoholic beverages in Q3. "Coronavirus has had a material impact on how and where people are consuming alcohol. While many bars, restaurants, and venues are currently closed or limiting service, consumers are still eager to connect and socialize with each other during this challenging period. People are turning to online platforms to reimagine the real-world social experiences that they are currently unable to comfortably enjoy in-person," said Ted Murphy, Founder and CEO of Izea.

11:05 EDT Shell, Microsoft form alliance to help address carbon emissions - Shell International Petroleum Company (RDS.A) and Microsoft Corporation (MSFT) are embarking on a new strategic alliance to support progress towards a world with net-zero emissions. This builds on the strong foundation of decades of technology collaboration between the two companies. This type of strategic alliance is a model for how companies can work together to achieve their net-zero ambitions. This strategic alliance will support Shell's ambition to be a net-zero emissions energy business by 2050, or sooner, in step with society and its customers. Shell's supply of renewable energy will help Microsoft deliver on its renewable energy supply goals and its broader ambition to be carbon negative by 2050. It is expected that over time the alliance will enable the two companies to achieve even more together. Highlights of the expanded alliance include: Shell will supply Microsoft with renewable energy, helping Microsoft to meet its commitment to having a 100% supply of renewable energy by 2025; The two companies will continue working together on artificial intelligence, which has already driven transformation across Shell's operations through access to real-time data insights, contributing to worker and onsite safety, and delivering efficiencies that have helped reduce Shell's carbon emissions; Shell and Microsoft will work together on new digital tools so Shell can offer its suppliers and customers effective support in reducing their carbon footprints; Shell and Microsoft will explore working together to help advance the use of sustainable aviation fuels; and The companies will use Microsoft's Azure cloud computing system and data from Shell assets to strengthen operational safety, by improving risk analysis, prediction and prevention.

10:36 EDT Lands & Buildings voices concerns over AIV's plan to separate - Land & Buildings Investment Management, a significant shareholder of Apartment Investment and Management Company, issued a public letter to the Company's Board of Directors. The letter read, in part, "Land & Buildings Investment Management, a large shareholder of Apartment Investment and Management Company, has significant concerns regarding the Company's announcement on September 14, 2020, of its plan to separate its business into two, separate and distinct, publicly traded companies, Apartment Income REIT and Aimco, through a reverse spin-off. We believe the proposed transaction will not close the Company's substantial discount to net asset value and is a thinly veiled attempt by management and the Board of Directors to rid themselves of a decades-long poor track record rather than address the fundamental issues challenging the Company. Specifically, shareholders will receive a taxable dividend of about 90% of the Company's coveted apartments in connection with the proposed spin-off. It is highly unlikely that both Aimco and AIR combined will trade anywhere close to AIV's stated NAV of $58 per share. What seems clear to us is that the proposed spin-off is not the result of an informed evaluation of all available opportunities to maximize shareholder value, particularly given the extraordinary appetite by private institutional investors for high-quality apartments. Completing a spin-off without fully and objectively evaluating all opportunities for the Company's real estate could result in material shareholder value destruction. Perhaps even more concerning, the Board and management appear to be rushing completion of the spin-off before shareholders would have the opportunity to express their views on this issue or elect Board members to better represent shareholder interests. As currently conceived, the proposed spin-off would be completed prior to the Company's 2021 Annual Meeting of Shareholders and without requiring a shareholder vote. By structuring the transaction as a taxable spin-off, the Board and management team have conveniently ducked shareholder approval of the transaction. We believe that shareholders deserve the right to express their views on such a material and potentially value-destroying plan. The proposed spin-off is far too important for the future value of AIV to be rushed through without shareholder support. We therefore call on the Board to immediately put the proposed spin-off to a shareholder vote. We also call on the Board to provide a fulsome explanation as to whether it fully explored all available strategic opportunities to maximize value for AIV, including a sale of the Company. Did the Board seek and/or receive any offers for the Company given the current discounted share price and robust private institutional demand for apartment assets? Is the proposed spin-off truly the most value-maximizing opportunity available or are the Board and management team attempting to jettison their lousy track records and avoid accountability at all costs? Shareholders deserve answers...Make no mistake: AIV is worth substantially more than its shares are trading for today. It seems clear to us that if the Board were interested in maximizing value for all shareholders, it would have thoroughly explored selling the Company closer to the $58/share NAV, 75% upside from yesterday's close, rather than have shareholders languish under Chairman and CEO Terry Considine post-spin at a substantial discount to NAV as it has under his leadership historically."

10:23 EDT AutoZone: Domestic SSS up 16.5% in August, down from May through July

10:20 EDT AutoZone believes sales will remain elevated 'for some time' - Comments taken from Q4 earnings conference call.

10:04 EDT Vail Resorts, PepsiCo expand partnership focused on waste reduction - Vail Resorts (MTN) and PepsiCo (PEP) announced an expansion of their partnership to 18 additional Vail Resorts locations across North America, including Whistler Blackcomb in British Columbia, Mount Snow in Vermont, and Hunter Mountain in New York. In addition to renewing and expanding their product distribution partnership to now 33 total resorts globally, PepsiCo committed to a "significant investment annually in projects that support Commitment to Zero, Vail Resorts' sustainability pledge to achieve a zero net operating footprint by 2030, including zero waste to landfill." Through a multi-year sustainability roadmap, the companies will focus on waste reduction, including reducing beverage and food packaging waste and replacing wax-lined paper cups with compostable or durable PepsiCo products. Vail Resorts and PepsiCo have already begun this work at select resorts. "At the end of the 2018/19 ski season, the companies shared that more than 250,000 wax-lined paper cups (or 7,750 pounds of waste) had been saved from landfill as a result of this switch at multiple on-mountain restaurants. In synergy with Vail Resorts' Commitment to Zero initiative, PepsiCo has its own target to make 100 percent of its product packaging recyclable, compostable, or biodegradable by 2025," they said in a statement.

10:02 EDT RedHill Biopharma: Brazil approves Phase 2/3 COVID-19 study with opaganib - RedHill Biopharma announced approval from the Brazilian Health Regulatory Agency for its ongoing global Phase 2/3 study evaluating opaganib in patients hospitalized with severe COVID-19 pneumonia. Opaganib is a first-in-class, orally-administered, sphingosine kinase-2 selective inhibitor with demonstrated dual anti-inflammatory and antiviral activity that targets a host cell component, unaffected by viral mutation, thus minimizing the likelihood of resistance. The company is in discussions with U.S. government agencies around potential funding to support the rapid advancement of opaganib toward potential emergency use approval.

10:00 EDT Cubic falls -7.0% - Cubic is down -7.0%, or -$4.17 to $55.39.

10:00 EDT ADC Therapeutics falls -11.0% - ADC Therapeutics is down -11.0%, or -$5.00 to $40.25.

10:00 EDT GameStop rises 18.8% - GameStop is up 18.8%, or $1.65 to $10.40.

09:47 EDT China Southern Airlines falls -4.1% - China Southern Airlines is down -4.1%, or -$1.19 to $28.01.

09:47 EDT Accel Entertainment falls -9.2% - Accel Entertainment is down -9.2%, or -$1.30 to $12.77.

09:47 EDT GameStop rises 17.8% - GameStop is up 17.8%, or $1.56 to $10.30.

09:31 EDT Health Canada approves Trulicity as adjunct to diet, exercise, therapy - On September 11, 2020, Health Canada approved Trulicity to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascular disease, as an adjunct to diet, exercise, and standard of care therapy. This decision makes Eli Lilly and Company's Trulicity the first and only GLP1 receptor agoniss approved to provide a cardiovascular benefit in people with multiple CV risk factors or with established cardiovascular disease. The new indication reflects the differentiated patient population of REWIND, the Trulicity cardiovascular outcomes trial. The study consisted primarily of people with multiple cardiovascular risk factors without established cardiovascular disease. REWIND showed a significant risk reduction in MACE-3, a composite endpoint of nonfatal myocardial infarction, non-fatal stroke or CV death. Results demonstrated consistent MACE-3 risk reduction with Trulicity across major demographic subgroups. Trulicity's safety profile was consistent with the GLP-1 RA class. The most common adverse events leading to the discontinuation of Trulicity were gastrointestinal events. In addition to its proven glycemic efficacy and easy-to-use device, Trulicity can now be prescribed to provide cardiovascular benefit to people with type 2 diabetes.

09:20 EDT iHeartMedia launches new podcast in partnership with Hillary Clinton - iHeartMedia announced "You and Me Both with Hillary Clinton," an iHeartRadio original podcast hosted by Hillary Clinton. The 24-episode show joins the iHeartPodcast Network beginning September 29 and will be available on iHeartRadio and everywhere else podcasts are heard. "You and Me Both with Hillary Clinton" will feature interviews with guests including Sarah Cooper, Gloria Steinem, Stacey Abrams, Aminatou Sow, Ann Friedman, Samin Nosrat, Patton Oswald, Tan France and more.

09:18 EDT Genius Brands appoints Marc Rosenberg as president of global brands, CMO - Genius Brands announced that Marc Rosenberg has been appointed President of Global Brands and CMO. Most recently, Marc Rosenberg was the CMO at Zizzle. Rosenberg will continue to own his current Edge Desk business, with the current management operating the day-to-day business with his oversight.

09:16 EDT Wolters Kluwer granted patent for LegalView BillAnalyzer technology by USPTO - Wolters Kluwer announced that the U.S. Patent and Trademark Office, or USPTO, has granted the company patent No. 10,733,675 for the artificial intelligence, or AI, technology behind LegalView BillAnalyzer. Wolters Kluwer introduced LegalView BillAnalyzer in 2017 to help corporate legal departments and insurance claims organizations more efficiently manage their incoming legal invoices and improve cost management. The proprietary AI-powered bill review automated scoring system is able to provide a high degree of accuracy and efficiency in the overall bill review process compared to non AI-powered bill review processes.

09:12 EDT Rogers Communications expands 5G network to five new cities - Rogers Communications announced it has launched 5G on Canada's most trusted and reliable network in Ajax, Burlington, Grimsby, Oakville and Whitby, Ontario, bringing consumers and businesses the very best in mobile wireless technology to their own neighbourhoods and business parks. Rogers 5G, powered by Ericsson, is the largest 5G network in Canada, now reaching 25 cities and towns in Ontario and more than 60 across Canada. These expansions build on the company's January roll out of 5G in downtown Montreal, Ottawa, Toronto and Vancouver.

09:11 EDT Emerson Electric gets contract to modernize Salto Grande Hydroelectric Complex - The Salto Grande Mixed Technical Commission has awarded Emerson a contract to modernize operations at the binational Salto Grande Hydroelectric Complex. The project is the first of a three-stage, 30-year, $960M investment to extend the life and improve the efficiency and safety of the 40-year-old complex located between Argentina and Uruguay. Beyond supplying renewable energy to parts of Uruguay and Argentina, the 1,890-megawatt Salto Grande facility regulates the flow of the Uruguay River, meeting the demand for drinking water supply and irrigation, preserving wildlife and ensuring the safety of local residents. Hydropower generates power by running water through turbines. The five-year contract calls for Emerson to modernize 14 hydroelectric turbine governors with its Ovation automation technology, designed to control and monitor hydropower operations. The solution includes measurement and machinery instrumentation for monitoring process conditions and will help provide reliable power generation that is highly responsive to the dynamic needs of the region's electrical grid.

09:09 EDT Green Cargo extends support agreement with Rimini Street for its SAP application - Rimini Street announced that Green Cargo, the Swedish state-owned rail logistics operator, has renewed and extended support and maintenance for its mission-critical SAP ECC 6.0 platform with Rimini Street. Green Cargo first switched to Rimini Street Support in 2017 and is continuing with the Company's ultra-responsive high-quality support model to enable the organization to continue to focus on its transformation initiatives - including the adoption of an agile, low-code application strategy - confident in the knowledge that its core SAP applications will remain stable and reliable under Rimini Street Support.

09:07 EDT Medtronic receives BDD status from FDA for TYRX - Medtronic has received Breakthrough Device Designation, or BDD, status from the FDA for the TYRX Absorbable Antibacterial Driveline Wrap, which is intended to securely hold a percutaneous driveline in patients receiving a ventricular assist device, VAD. A vital component of VAD systems, the driveline connects the implanted heart pump to an external controller that is powered by an AC or DC adapter, or external batteries. The pump increases the amount of blood that circulates through the body in patients with advanced heart failure.

09:07 EDT Ralph Lauren to reduce global workforce by the end of FY21 - Ralph Lauren announced steps to accelerate its "Next Great Chapter" plan, which include establishing a simplified global organizational structure and rolling out enhanced technology platforms to support the company's global operations. Ralph Lauren announced plans to reduce its global workforce by the end of the company's FY21, which is expected to result in gross annualized pre-tax expense savings of approximately $180M-$200M, with savings realization primarily beginning in the company's FY22. In connection with the reduction in workforce, the company expects to incur total estimated pre-tax charges of approximately $120M-$160M. In addition to the actions announced, the company anticipates additional actions associated with the aforementioned initiatives as part of the FY21 strategic realignment plan. The company is transforming how it operates with the implementation of new technology platforms across several areas of its business. This includes rolling out a cloud-based human resources and planning system globally. This is a company-wide initiative to digitize the product journey. "The changes happening in the world around us have accelerated the shifts we saw pre-COVID, and we are fast-tracking some of our plans to match them - including advancing our digital transformation and simplifying our team structures," said Patrice Louvet, president and CEO. "These steps will enable us to progress our brand elevation journey and deliver Ralph's vision in today's dynamic environment - inspiring our consumers around the world and creating value for all of our stakeholders."

09:05 EDT Google Cloud, Anaplan team to offer Anaplan's enterprise platform on Google - Google Cloud (GOOG) and Anaplan (PLAN) announced a strategic partnership to offer Anaplan's platform for enterprise planning and business performance on Google Cloud. As Anaplan's first public cloud offering, the partnership brings customers added intelligence, choice, and scalability to solve complex business problems and link business strategy to operational drivers and financial outcomes. An Anaplan customer since 2016, Google has deployed the Anaplan platform on Google Cloud with multiple use cases across sales, supply chain and finance. With Anaplan on Google Cloud, global enterprises can leverage the leading performance of Anaplan's in-memory, Hyperblock calculation engine running on Google Cloud's global, high-performance, scalable and secure infrastructure. In addition, the partnership will enable Anaplan to expand its global reach so customers can benefit from using Anaplan at closer proximity to their operations with greater choice and control to comply with local and industry-specific data residency and compliance requirements. To help businesses improve decision-making and planning, Google Cloud and Anaplan, together with services partners, will offer an extended platform for data storage and analytics, leveraging BigQuery and Google Cloud's AI/ML capabilities. These integrations will enable organizations to blend first-party Anaplan data with third-party data sources for dynamic, real-time modeling of large amounts of critical data to deliver new business insights. "We are committed to helping businesses modernize and accelerate their most critical operations with Google Cloud," said Thomas Kurian, CEO at Google Cloud. "Through our partnership with Anaplan, we are bringing highly performant infrastructure and intelligent innovation to enterprise planning, ultimately helping organizations make better business decisions."

09:05 EDT Anaplan, Google Cloud announce strategic partnership - Google Cloud (GOOG, GOOGL) and Anaplan (PLAN) announced a strategic partnership to offer Anaplan's platform for enterprise planning and business performance on Google Cloud. As Anaplan's first public cloud offering, the partnership brings customers added intelligence, choice, and scalability to solve complex business problems and link business strategy to operational drivers and financial outcomes. An Anaplan customer since 2016, Google has deployed the Anaplan platform on Google Cloud with multiple use cases across sales, supply chain and finance.

09:02 EDT Tecogen receives order for multiple Ultera emission reduction systems - Tecogen announced the sale of two of its proprietary Ultera emissions reduction systems for use by the Eastern Municipal Water District at its facility in Winchester, California. The sale is the second phase of the project, following completion of the engineering for the larger Ultera system required for the 800-horsepower natural gas Caterpillar engines being procured for the project. The pumps at the installation site were previously powered by engines that are being replaced by EMWD in part to ensure compliance with the highly stringent emissions requirements of the South Coast Air Quality Management District. SCAQMD has jurisdiction over air regulatory matters in large portions of Riverside, Los Angeles, Orange, and San Bernardino Counties.

09:01 EDT Soliton names Greater Than One Group as its integrated marketing agency - The company states: "Soliton announced that it has selected Greater Than One Group as its integrated marketing agency. The collaboration will aim to raise the visibility of the company's Rapid Acoustic Pulse device and establish the Soliton brand in the aesthetic industry through multi-channel marketing efforts. Soliton's decision to partner with GTO comes as the Company approaches initial U.S. commercialization of its Rapid Acoustic Pulse device in the first half of 2021."

08:59 EDT IAC's Dotdash acquires Simply Recipes and Serious Eats, terms not disclosed - Dotdash announced its acquisition of food and recipe sites Simply Recipes and Serious Eats from Fexy Media. This is the fifth acquisition for Dotdash since the beginning of 2019. The deal closed September 21.

08:48 EDT Neogen CEO: Conditions across many markets 'remain sluggish and challenging' - "Considering the ongoing difficult global business climate, we are pleased to report increased revenues and net income as we continue to take the necessary measures to protect our employees and business - and the global food supply," said John Adent, Neogen's president and CEO. "Although conditions across many of our markets remain sluggish and challenging, the first quarter showed Neogen's resilience to difficult conditions due to the diversity of our portfolio of products and services. As our food safety markets faced disruption, we continued to have strong growth in our genomics business - and we worked to meet the global demand for our biosecurity products, including cleaners, disinfectants, and hand sanitizers. We are also pleased with the tremendously positive market reaction following the recent launch of our next generation automated general microbiology test system, Soleris NG."

08:47 EDT Document Security reiterates plans for Impact Biomedical share dividend - Document Security Systems reiterates its plans for its previously announced Impact BioMedical share dividend. The first tranche of the two-part special share dividend was announced in August 2020, and DSS shareholders of record as of the record date of 5:00 p.m. ET on September 7, 2020 earned a bonus of two shares of Impact BioMedical for every one share of DSS common stock held as of the Record Date. Shareholders are not required to hold their DSS shares beyond the Record Date to receive the Bonus Shares. The Bonus Shares are expected to be issued after an IPO of Impact BioMedical, which the Company is targeting in 2021. While there can be no assurance that Impact BioMedical will be taken public and/or that any Bonus share distribution will occur, particularly due to unforeseen circumstances including fulfilling the pre-requisite criteria during the IPO application process and market forces beyond the Company's control, it is the intention of management and the Board to take Impact BioMedical public. A second tranche of the special share dividend is expected to provide an additional two shares of Impact BioMedical for each common share of DSS held at a yet to be determined record date. DSS announced the closing of its acquisition of Impact BioMedical on August 21, 2020. Impact BioMedical's ownership of a suite of antiviral and medical technologies has been valued at $382M by Destum Partners, known globally for its high level of expertise and capability in independently valuing and advising on pharmaceutical technology. On May 26, 2020, Impact BioMedical disclosed that it received a valuation of $933M for this suite of technology from a different independent valuation firm. Unlike the previous valuation, the new valuation takes into consideration numerous additional disease applications of the suite of antiviral and medical technologies.

08:42 EDT Intercontinental Exchange announced that Citi has joined the ICE ETF Hub - Intercontinental Exchange (ICE) announced that Citi (C) has joined the ICE ETF Hub as an authorized participant. Citi was a founding member of the ICE ETF Hub advisory committee, providing early feedback on the design of the platform. "As an early member of our advisory committee, Citi has provided valuable insights and constructive guidance, which have been critical in improving the platform and bringing more efficiencies to the ETF primary market. Because of this, we're particularly excited to have them join the platform as an authorized participant," said Peter Borstelmann, President of ICE Bonds and Head of ICE ETF Hub. ICE ETF Hub is an industry-wide, open architecture, technology solution, offering a more standardized and simplified process for the creation and redemption of ETF shares. It currently supports both US-listed domestic equity and fixed income ETFs.

08:40 EDT PFSweb to open fulfillment distribution center in Belgium - PFSweb is opening an additional fulfillment distribution center in Liege, Belgium. As a part of its operations business unit, PFS, the company operates multiple fulfillment centers to support its operations across the world. The new facility in Belgium expands the PFS global fulfillment center footprint to nine facilities. Similar to the new PFS facility in the Dallas area announced in August, this expansion allows PFS to expand daily output capacity in mainland Europe for key client expansions as the peak holiday season approaches. The facility is near the existing Liege fulfillment center operated by PFS since 1999. This strategic location along the Canal Albert will allow for faster outbound delivery into the Netherlands and Germany, and will serve as an advantageous location for inbound product flow through boat containers. The first client in this facility is scheduled to go live in Q4 2020.

08:39 EDT Pulmatrix provides update on product pipeline - Pulmatrix (PULM) provides an update on product pipeline. "COVID-19 has presented us with some challenges, but we are positioned to make progress across our product pipeline," said Ted Raad, Chief Executive Officer of Pulmatrix. "During 2020, Pulmatrix has raised over $30M through partnerships and public financing, allowing us to advance three programs towards potential proof of concept data." PUR1800: Patient dosing for the PUR1800 Ph1b is planned to start in Q1 2021 and expects both the Ph1b and 6-month toxicology data in Q3 2021. Delivery of the Ph1b study clinical study report will trigger a $2M milestone payment from Johnson & Johnson (JNJ) under the option to license agreement with Johnson & Johnson. PUR3100: company is advancing a program in migraine, a disorder with over 30M patients and significant unmet need. Company anticipates having a lead formulation for a non-clinical PK study in Q4 2020. Pulmazole: Together with partner Cipla Technologies, they decided to end hase 2 clinical study of Pulmazole for the treatment of asthma patients with ABPA. COVID-19 had a significant impact on enrollment in the first half of this year and the study was initially put on hold as the pandemic spread in 2Q 2020.

08:37 EDT Blackstone announces $8B final close for BREDS IV - Blackstone announced the final close of its most recent real estate debt fund, Blackstone Real Estate Debt Strategies IV, or BREDS IV. The company said BREDS IV has $8B of total capital commitments, making it the largest real estate credit fund ever raised. Blackstone Real Estate Debt Strategies has $26B of assets under management, and Blackstone Real Estate has a total of $167B of investor capital under management as of Q2. BREDS IV will have flexible capital to lend around the globe and will deploy a variety of investment strategies, including lending, liquid securities, structured solutions to financial institutions and corporate credit.

08:36 EDT Simulations Plus teams with pharma firm to validate new AIDD module - Simulations Plus announced that it entered into a collaborative research agreement with a large pharmaceutical company to evaluate the new AIDD Module in the recently launched version of ADMET Predictor. Per the terms of the collaboration, the partner company has entrusted Simulations Plus with compound structure and activity data from one of their ongoing drug discovery programs. The computational chemists at Simulations Plus worked with the partner's team to define the multi-objective parameters against which the lead molecule(s) needed to be optimized. The innovative approaches within the AIDD Module are now being unleashed to produce novel libraries of virtual compounds with excellent predicted combinations of the properties we chose. Selected sets of analogs will be synthesized and tested to complement the in-house development program and assess the merits of the AIDD approach, with results expected to be jointly shared.

08:36 EDT BeyondSpring appoints Elizabeth Czerepak as CFO - Following its recent receipt of two Breakthrough Therapy Designations in both the U.S. and China for Plinabulin in the chemotherapy-induced neutropenia indication, BeyondSpring announced the appointment of Elizabeth Czerepak as CFO effective immediately. Simultaneously, Seed Therapeutics, Inc., BeyondSpring's new subsidiary focused on a targeted protein degradation platform to attack previously believed undruggable targets, has appointed Edward Liu as CFO. Mr. Liu will also retain his responsibilities as CFO of BeyondSpring, China. Czerepak recently served as CFO and Chief Business Officer for Genevant Sciences.

08:36 EDT Future FinTech to acquire 51% of Spondula for $3.06M - Future FinTech Group announced it has signed a term sheet with Spondula, a company incorporated in the UK and the selling shareholder of Spondula on September 19. Pursuant to Term Sheet, the Company plans to acquire 51% of the total issued and outstanding shares of Spondula. The Term Sheet is non-binding except for the "Exclusivity", "Confidentiality" and "Governing Law" sections. According to the Term Sheet, FTFT or its subsidiary will acquire 51% of the total issued and outstanding shares of Spondula through a share exchange with the shareholder of Spondula. Spondula is located in the UK and it operates a global banking and money transfer platform serving both individuals and businesses. According to Term Sheet, the acquisition price is expected to be $3.06M and the consideration will be paid in FTFT's common stock, and the price of FTFT's common stock will be based on the average closing price of FTFT's common stock on the Nasdaq for the 10 trading days prior to the signing date of the definitive agreement. The parties also agreed to set rules for Valuation Adjustment Mechanism.

08:35 EDT Future FinTech to acquire 51% of Spondula for $3.06M - Future FinTech Group announced it has signed a term sheet with Spondula, a company incorporated in the UK and the selling shareholder of Spondula on September 19. Pursuant to Term Sheet, the Company plans to acquire 51% of the total issued and outstanding shares of Spondula. The Term Sheet is non-binding except for the "Exclusivity", "Confidentiality" and "Governing Law" sections. According to the Term Sheet, FTFT or its subsidiary will acquire 51% of the total issued and outstanding shares of Spondula through a share exchange with the shareholder of Spondula. Spondula is located in the UK and it operates a global banking and money transfer platform serving both individuals and businesses. According to Term Sheet, the acquisition price is expected to be $3.06M and the consideration will be paid in FTFT's common stock, and the price of FTFT's common stock will be based on the average closing price of FTFT's common stock on the Nasdaq for the 10 trading days prior to the signing date of the definitive agreement. The parties also agreed to set rules for Valuation Adjustment Mechanism.

08:34 EDT Stratus Properties adopts limited-duration shareholder rights plan - Stratus Properties announced that its board has unanimously adopted a limited-duration shareholder rights plan to ensure shareholders have the benefit of the previously announced exploration of a potential conversion to a real estate investment trust, or REIT. The rights plan is intended to reduce the likelihood that concentrated share ownership adversely impacts the company's ability to qualify as and be taxed as a REIT. In order to qualify as a REIT, among other requirements, not more than 50% of a company's shares may be beneficially owned by five or fewer individuals. The rights plan is effective immediately and the record date for the rights distribution is October 2. The rights will expire on September 22, 2023. However, the rights will expire prior to that date at the earlier of the time at which the company's conversion to a REIT becomes effective and the close of business on December 31, 2021, unless shareholder approval has been obtained on or prior to such date. The rights will be exercisable only if a person or group acquires beneficial ownership of 9.8% or more of the outstanding common stock of Stratus. Any shareholders with beneficial ownership of 9.8% or more of the outstanding common stock of Stratus as of the time of this announcement are grandfathered at their current ownership levels. Shareholders are not required to take any action to receive the distribution of their rights.

08:33 EDT Hilger achieves ISO 45001: 2018 Occupational Health and Safety Certification - Dynasil announces that its subsidiary Hilger Crystals has achieved certification for the ISO 45001:2018 Occupational Health and Safety Standard. It is the first of all Dynasil subsidiaries to meet accreditation of the three integrated management systems standards: ISO 9001, ISO 14001, and now ISO 45001. ISO 45001:2018 specifies an international benchmark for organizations to identify, control, and decrease risks associated with occupational health and safety and an organizational commitment to continual improvement of its systems to ensure an ever safer and healthier workplace. Adherence to this standard also improves overall business performance by increasing productivity and reducing workplace illness and injury.

08:32 EDT Sectigo selected by Baidu - Sectigo announced that Baidu has chosen Sectigo to provide the back-end services for the company's all-new Baidu Trust SSL Certificates. Baidu will offer Sectigo Domain Validated, Organization Validated, and Extended Validation certificates white-labeled under the Baidu Trust product line, greatly expanding Sectigo's footprint in Asia.

08:26 EDT Nano-X slides as another prominent short-seller calls it 'piece of garbage' - Shares of Nano-X Imaging are down $4.57, or 15.9%, to $24.26 in pre-market trading after Carson Block's Muddy Waters Research said that it is short the stock, joining Andrew Left's Citron Research, which previously claimed in the firm's own short report that shares of Nano-X Imaging are heading to zero. In Muddy Waters' newly published report, the firm stated in part: "We are short NNOX because we think it is a much bigger piece of garbage than Nikola will ever be. There are important similarities, though. Nikola rolled a truck down the hill to try to prove it's real. NNOX almost certainly used somebody else's chest images to try to make its ARC machine look real... But NNOX gets much worse. A convicted felon, who crashed an $8 billion market cap dotcom into the ground, was seemingly instrumental in plucking NNOX out of obscurity and bringing its massively exaggerated story to the U.S. NNOX touts distribution partnerships that supposedly amount to $180.8 million in annual commitments. Almost all of the company's partnerships give reason for skepticism... If NNOX's claims are achievable, it seemingly will come as a shock to most of the radiology profession. We interviewed five radiologists who were familiar with NNOX's claims. Not a single one expressed credulity of NNOX. Four of the radiologists - without any prompting - compared NNOX to Theranos... We conclude that NNOX has no real product to sell other than its stock." Reference Link

08:18 EDT Aqua Metals announces intention to sell McCarran, Nevada plant - Aqua Metals announced that as part of its accelerated equipment supply and licensing strategy, which includes the disposition of non-core assets, the Company has officially placed its novel lead acid battery recycling plant for sale. The Company built and then operated the demonstration plant commercially through 2019 and successfully manufactured over 35,000 ingots of ultrapure AquaRefined lead. The Company believes it has achieved the demonstration purposes of the plant, resulting in the successful validation of AquaRefining technology and commercial sale of ultrapure lead. As stated previously, and as part of its long-term business strategy, the Company now plans to monetize this non-core asset with the sale of the plant as a means of financing the Company's continued acceleration of its core business of becoming an equipment supplier and licensor of AquaRefining technologies. The Company intends to market the land and building as a general use industrial facility. Residing on 11.5 acres, the 136,000 square foot plant contains 14,000 square feet of operational office space. The facility also includes three exterior dock doors with seven exterior grade level doors, 13,000 amps of total building power and a temperature-controlled warehouse with negative or positive pressure. The Company has also initiated a separate effort to sell certain non-core lead recycling equipment into the secondary market for used equipment. The Company believes the land, building and non-core equipment may have a strong attraction as a fully-integrated package for any buyer looking to engage in lead recycling activities. The Company expects to apply the cash proceeds from the sale of the plant to further strengthen its balance sheet. The Company believes the sale proceeds, potential future insurance collections and the $20.3M in insurance collected to date will be sufficient to fully fund the AquaRefining licensing business strategy as the Company transitions towards scalable revenues.

08:16 EDT Cresco Labs announces approval, location of tenth Illinois dispensary - Cresco Labs announced the approval and the location of its tenth Illinois dispensary in Naperville. The adult-use dispensary is located in one of the shopping areas in Naperville, the third largest city in Illinois with approximately 150,000 residents. Upon final approval from the State of Illinois for the Naperville location, Cresco will operate the maximum allowed ten dispensaries in Illinois. Total Illinois cannabis retail sales were $95M in August while total sales through the first eight months of 2020 were $600M in the state.

08:12 EDT Harbor Custom Development enters purchase, sale agreement for rental project - Harbor Custom Development announced that it has entered into a purchase and sale agreement for the acquisition of 9.6 acres of land in Port Orchard, Washington for a price of $1.44M. The purchase is expected to close on or before June 1, 2021, contingent upon permit approval. The property, approximately a twenty-minute drive to Tacoma, and ten minutes to the fast ferry terminal to Seattle's Central Business District, is earmarked by Harbor as a joint venture for the development of a 144-unit multi-family garden style apartment complex featuring studio, one - and two-bedroom units with diversified floor plans. It will be Harbor's initial entry into the Port Orchard rental market. Port Orchard, which is located in Kitsap's County, has seen a 60% increase in its population from 2009 to 2018 and, as a result, demand for apartment rentals has increased substantially during the period.

08:11 EDT SG Blocks announces asset purchase agreement to acquire ECHO DCL - SG Blocks announced that it has entered into an agreement to acquire substantially all of the assets of ECHO DCL, except for ECHO DCL's real estate holdings, for which SG Echo has obtained a right of first refusal to acquire same, in a cash and stock transaction. ECHO DCL is a container and modular manufacturer, and current supplier to SG Blocks based in Durant, Oklahoma specializing in the design and construction of permanent modular and temporary modular buildings. The agreement to acquire substantially all the assets of ECHO DCL, except for ECHO DCL's real estate holdings, for which SG ECHO obtained a right of first refusal to acquire same, is subject to customary closing conditions and expected to close on or before September 23. Terms of the acquisition provide for the payment to Echo of $1.06M in cash at closing, subject to the escrow of certain of the purchase price funds, and the payment of certain of Echo's indebtedness by SG Echo, including the obligation to satisfy a guidance line of credit loan, or GLOC Loan, in the principal amount of approximately $616,000, pay the debt service on certain of Echo's indebtedness in the approximate principal amount of $1.7M for 12 months following the closing, payoff at maturity a certain line of credit of Echo with BTH Bank in the principal amount of $500,000 and the payment of earn out payments equal to the net income received from the acquired business during the three-month period beginning on the first day of the first full month that is three months after the closing date, the three-month period following the first earn out period and the three-month period following the second earn out period, payable in 50% in cash and 50% in shares of the company's common stock to be valued a $2.50 per share; provided, that up to approximately $300,000 of any amounts paid in respect of the GLOC Loan, and any amounts paid in respect of the debt service on Echo's indebtedness and line of credit with BTH Bank, shall be offset against and reduce the earnout payments due to Echo. In no event may the number of shares of common stock to be issued to Echo exceed 19.99% of the company's outstanding shares on the date of the agreement.

08:09 EDT BlackBerry Spark selected by United States Air Force for secure productivity - BlackBerry announced that the United States Air Force has selected BlackBerry Spark for their secure productivity needs. The agreement gives the organization access to the latest BlackBerry technologies for Unified Endpoint Management and Unified Endpoint Security.

08:08 EDT Sinovac starts clinical trials for COVID-19 vaccine candidate in Turkey - Sinovac Biotech announced that it has recently commenced phase III clinical trials for its inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences, Sinovac LS, or "CoronaVac," in Turkey. The phase III clinical trial seeks to test efficacy and safety of CoronaVac in Turkey and aims to be a pivotal study to support the licensure of this product. This case-driven, randomized, double-blinded and placebo-controlled phase III clinical trial uses an adaptive design, and all participants will be enrolled in a step-by-step basis. In the first stage, 1,300 healthcare workers between the ages of 18-59 years old will be randomly to receive two doses of vaccine or placebo at a two-week interval. In the second stage, approximately 12,000 members of the general population between the ages of 18-59 years old will be enrolled to receive two doses of vaccine or placebo at a two-week interval. In recent months, the Company's Phase I/II clinical trials of CoronaVac in adults and elderly volunteers were conducted in China's Jiangsu and Hebei Provinces on April 16th and May 22nd, respectively. The vaccine candidate appeared to be well tolerated for different dosage and no serious vaccine-related adverse events were reported, demonstrating a good safety profile for the vaccine candidate. Both seroconversion rates in adults and elderly volunteers were above 90%, indicating favorable immunogenicity of CoronaVac. In addition to Turkey, the Company has partnered with several companies outside of China for phase III efficacy studies.

08:07 EDT Chipotle to bring back Carne Asada for a limited time - Chipotle Mexican Grill announced it is bringing back Carne Asada to restaurants across the U.S. for a limited time. The premium steak option will also return to the menu in Canada and make its debut in France, where it will become Chipotle's first new protein introduced in the European market.

08:05 EDT Origin Agritech receives testing standard approval for two GMO corn traits - Origin Agritech announced that the Standard Testing Method and Procedures of the company's two GMO corn seed traits have been approved in a newly published National Standards Catalog by The Ministry of Agricultural and Rural Affairs of China. The traits that received the National Testing Standard approval are G1105E-823C, a double stack of insect resistance and herbicide tolerance corn and GH5112E-117C, an herbicide tolerance corn.

08:05 EDT Entergy announces power restoration in Lousiana after hurricane Laura - Following Hurricane Laura making landfall near Cameron, Louisiana in the early morning of Aug. 27, Entergy Corporation announced its utilities have restored power to approximately 910,000 customers who can accept power, or approximately 99% of customers affected by the storm. Crews have restored power to all customers in Texas and are making significant progress in the remaining hardest hit areas of Southwest Louisiana. Hurricane Laura was the strongest storm to make landfall in Louisiana in 164 years and is tied for the fifth strongest to make landfall in the continental United States.

08:04 EDT Party City to hire approx. 20,000 employees for Halloween season - Party City announced that it plans to hire approximately 20,000 temporary employees and open approximately 25 Halloween City pop-up stores for the Halloween season to support consumers' needs however they choose to celebrate and shop this year. The Company expects to retain about 10 percent of these employees following the Halloween season. To help "You Boo You," Party City will continue to offer the safety and convenience of its contactless shopping experiences including curbside pickup, same day delivery, online shopping and in-store contactless mobile phone payments to check out quickly. Customers can also enjoy Party City's legendary costume wall virtually online or through the Party City app, which has resources and creative ideas on how to dress up, celebrate and decorate, with access to everything you need to make Halloween feel extra special or spooky this year, including a wide variety of stylish new face masks that complement any costume.

08:03 EDT Mustang Bio announces Orphan Drug Designation for MB-207 - Mustang Bio announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to MB-207, Mustang's lentiviral gene therapy for the treatment of patients with X-linked severe combined immunodeficiency, also known as bubble boy disease, who have been previously treated with a hematopoietic stem cell transplantation and for whom re-treatment is indicated. In August 2020, the FDA granted Rare Pediatric Disease Designation to MB-207 for the treatment of XSCID in previously treated patients with HSCT. The lentiviral gene-therapy method employed in MB-207 was co-developed by scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and St. Jude Children's Research Hospital MB-207 has been studied at NIAID since 2012 and continues to be assessed in a NIAID-supported Phase 1/2 clinical trial for XSCID in patients over the age of two who have received prior HSCT. Mustang expects to file an investigational new drug application with the FDA to initiate a multi-center pivotal Phase 2 clinical trial of MB-207 in this patient population in the fourth quarter of 2020. An additional Phase 1/2 clinical trial for XSCID in newly diagnosed infants under the age of two is ongoing at St. Jude, UCSF Benioff Children's Hospital in San Francisco and Seattle Children's Hospital. The product candidate in this trial is designated as MB-107. In May 2020, Mustang submitted an IND to the FDA to initiate a multi-center pivotal Phase 2 clinical trial of MB-107 in newly diagnosed infants with XSCID who are between two months to two years of age. The trial is expected to enroll 10 patients who, together with 15 patients enrolled in the current multi-center trial led by St. Jude, will be compared with 25 matched historical control patients who have undergone HSCT. The primary efficacy endpoint will be event-free survival. The initiation of this trial is anticipated in the fourth quarter of 2020. Mustang is targeting top-line data from this trial in the second half of 2022. The FDA previously granted Rare Pediatric Disease, Orphan Drug and Regenerative Medicine Advanced Therapy Designations to MB-107 for the treatment of XSCID in newly diagnosed infants. Additionally, the European Medicines Agency granted Advanced Therapy Medicinal Product Classification to MB-107.

07:56 EDT Lantern Pharma announces research agreement with Fox Chase Cancer Center - Lantern Pharma announced a collaboration and research agreement with Fox Chase Cancer Center for the further development of Lantern's LP-184 in pancreatic cancer. Based in Philadelphia, Fox Chase is a leading research center for pancreatic cancers and one of the four original cancer centers to receive comprehensive cancer center designation from the National Cancer Institute, or NCI. The Fox Chase collaboration will focus on advancing the targeted use of LP-184 in molecularly-defined sub-types of pancreatic cancer.

07:48 EDT United Rentals announces chief commercial officer Paul McDonnell leaving - United Rentals announced that Paul McDonnell, chief commercial officer, will leave the company on September 30. McDonnell will continue to provide advisory services to United Rentals in an independent capacity for 24 months. His leadership responsibilities with respect to sales and specialty operations will be absorbed under Dale Asplund, chief operating officer. Matthew Flannery, chief executive officer of United Rentals, said, "We thank Paul for his significant contributions to the success of our company, both as a talented leader and a strong advocate for our customers. He led the growth of our specialty rental segment to the largest network of its kind in the world. I'm pleased that Paul will remain available to us, and I join our executive team in wishing him continued success."

07:44 EDT Walmart teams up with Goldman to offer online sellers business credit lines - Walmart (WMT) is partnering with Goldman Sachs (GS) to provide lines of credit to third-party merchants who sell their products on Walmart.com, Walmart said in a statement. "Starting today, eligible Marketplace sellers will be invited to apply for lines of credit offered by Marcus by Goldman Sachs. Access to affordable capital is more important than ever as businesses large and small work to adapt and evolve to serve customers and grow their businesses. Initially, approved sellers will have access to lines of credit from Marcus between $10,000 - $75,000, and plans are to substantially increase the maximum line amount available in the future." Reference Link

07:38 EDT Auxly's KGK Science receives research license to conduct testing with humans - Auxly Cannabis Group announced that its wholly owned subsidiary, KGK Science has received its second Cannabis Research Licence from Health Canada pursuant to the Cannabis Act. This licence permits KGK to administer cannabis extracts, edible cannabis and cannabis topicals to human subjects for purposes of palatability and sensory testing at its clinical research facility located in London, Ontario. Sensory evaluation measures, analyzes and interprets the reaction of human subjects to products as perceived by the senses, it is an incredibly valuable tool in understanding and determining consumer preferences and the basis for those differences. As the cannabis industry continues to expand and new products are being introduced to the market, KGK will be able use their existing database of over 25,000 participants to provide palatability and sensory studies to all licenced producers across Canada that are seeking to undertake controlled focus groups on any cannabis product development initiatives.

07:34 EDT CoreLogic urges shareholders to vote against Senator/Cannae proposals - CoreLogic filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its upcoming Special Meeting of Shareholders on November 17. The proxy statement and other important information related to the Special Meeting can be found at CoreLogicValue.com. The CoreLogic Board of Directors unanimously recommends shareholders vote against the removal of CoreLogic's directors using the WHITE proxy card, so that the Company can continue to execute on its successful strategy for sustainable growth and substantial shareholder value creation. We are delivering outstanding financial and operational performance. Our strong financial results in 2020 are supported by increasing organic growth and recurring revenues as well as record profitability, margins, and free cash flow. We have just raised financial guidance for 2020 and 2021, which underscores our high confidence in CoreLogic's future and the value-creation opportunities inherent in continued execution of our strategic plan. The company believes it is poised for significant valuation upside, which shareholders will not benefit from under Senator/Cannae's inadequate acquisition proposal. The Board remains open to all paths to create value, but we are confident in our view that we will produce value for shareholders far in excess of $66.00 per share. CoreLogic has provided significant transparency and detailed information to all shareholders, including Senator and Cannae, through multi-year projections, margin targets, planned divestitures and capital allocation plans, that we believe clearly demonstrates that CoreLogic is worth substantially more than $66.00 per share.

07:32 EDT Frequency Therapeutics completes patient enrollment of FX-322 - Frequency Therapeutics announced the completion of enrollment of its Phase 2a study of FX-322 for sensorineural hearing loss, or SNHL. The company anticipates obtaining full results for the study, in which 95 patients were enrolled, in Q2 of 2021.

07:21 EDT Lexaria Bioscience granted DehydraTECH technology patent from USPTO - Lexaria Bioscience announced that it has received another new granted patent in the U.S. Lexaria has been granted U.S. Patent No. 10,756,180 pursuant to the notice of allowance it received from the United States Patent and Trademark Office, or USPTO, for patent application number 16/497,920 previously announced on April 23, 2020. This new patent provides patent claims that protect the use of Lexaria's DehydraTECH technology together with cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, or vitamins in mix and serve beverage formats. This signifies another addition to Lexaria's first patent family, under which nine U.S. patents have now been granted.

07:14 EDT AIM ImmunoTech announces pancreatic cancer survival results from EAP - AIM ImmunoTech announced receipt of statistically significant pancreatic cancer survival results from a multi-year early access program, or EAP. conducted at Erasmus University Medical Center in the Netherlands. Casper van Eijck and his team at Erasmus MC found a statistically significantly survival benefit when using Ampligen in patients with locally advanced/metastatic pancreatic cancer after systemic chemotherapy. Prof. van Eijck states, "The overall survival of the experimental group was compared to a large historical control cohort matched for age, gender, stage of disease, and number of cycles of Folfirinox chemotherapy. Median survival was approximately two-fold higher, that is 200%, in the Ampligen arm as compared to the historical controls. These results were obtained with a very high degree of statistical significance. Based on these data, I see the potential for Ampligen as a meaningful extension of the standard of care for advanced pancreatic cancer, which we are planning to investigate further." AIM will work with its contract research organization, Amarex Clinical to seek FDA fast-track and possibly even FDA breakthrough designations and to obtain IND authorizations to conduct a follow-up pancreatic cancer Phase 2/3 clinical trial with sites in the Netherlands at Erasmus MC under Prof. van Eijck, and also at cancer research centers in the United States. AIM also plans to file dual orphan drug status applications for use of Ampligen in the treatment of late-stage pancreatic carcinoma with the FDA and the European Medicines Agency, or EMA. If granted, this serves to extend a company's exclusivity rights once a drug reaches market.

07:11 EDT UCB: FDA, EMA accept BLA, MAA for bimekizumab - UCB announced that the FDA and EMA have accepted the Biologics License Application and Marketing Authorization Application, respectively, for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis.

07:09 EDT Medipharm Labs to supply cannabis oil to XLR8 Brazil - MediPharm Labs announced its wholly owned subsidiary MediPharm Labs will supply premium, GMP-certified formulated cannabis oil to XLR8 BRAZIL. Under the two-year agreement commencing from the time of product authorization, MediPharm Labs Inc. will provide a variety of cannabis concentrate formats for patient-ready formulated products that will be distributed by XLR8 to leading pharmacies and other authorized channels in Brazil. The initial product SKUS include a 20:1 CBD rich product and a 10:10 balanced THC and CBD formulation. XLR8 will obtain ANVISA Sanitary Product Authorization and undertake the process for final Product Registrations.

07:08 EDT GDS Holdings announces accepted offer to acquire Beijing data center - GDS Holdings announced that it has extended a legally-binding offer to acquire 100% of the equity interests in target companies which own a major data center in the Shunyi district of Beijing. The target companies are owned by a private equity fund controlled by CITIC Private Equity Funds Management and its affiliated parties. The offer has been accepted, with exclusivity terms agreed by both parties. The total enterprise value of the Acquisition is approximately RMB3.8B, with a further RMB500M contingent on the acquisition by the target companies of the property interests in the site. BJ14 is one of the largest and highest quality data center assets in the Beijing market. It is located adjacent to the Company's Beijing 5 data center and 8 kilometers from its data center campus comprised of Beijing 10, 11, and 12, forming a cluster in the Shunyi District of Beijing which can generate significant operation synergies. BJ14 has a net floor area of over 19,000 sqm. It is fully committed by five hyperscale customers, including a new large internet customer logo. BJ14 is fully operational and is currently approximately 68% utilized. It is expected to be fully utilized in 2022. This transaction is subject to entry into definitive agreements as well as the completion of certain conditions precedent to the closing of the transaction. We cannot assure you that any definitive agreement will be signed or, if such definitive agreement is signed, that the conditions precedent to the closing of the transaction will be satisfied, in which case the proposed transaction will not be consummated.

07:07 EDT NeuroMetrix launches Quell app for Apple Watch - NeuroMetrix (NURO) reported the launch of the Quell Watch App, now available for download from the Apple App (AAPL) store. Quell is a wearable, transcutaneous electrical nerve stimulation device for knee, foot and leg pain that is available over-the-counter. It can be used during the day while active and at night while sleeping. Users can personalize and manage therapy discreetly via the mobile app for iPhone and Android smartphones. Quell is also a pain management solution with pain, sleep, activity and gait tracking. The Quell Health Cloud provides customized feedback and powers one of the largest chronic pain outcomes databases. T The Quell Watch app is standalone, so it functions independently of the iPhone. It gives a Quell user the ability to control the device and monitor pain relief from the wrist; a level of convenience never before achieved with a TENS device. The user simply taps the Quell complication to open the app. The user can then easily start or stop therapy, increase or decrease intensity, view their therapy schedule, and get Quell status information. The battery level can be checked by just glancing at the complication.

07:06 EDT Orthofix, Neo Medical in pact to develop, market single-use spinal solutions - Orthofix Medical announced a partnership and investment agreement to develop and market innovative outcome-driven procedural solutions. The collaboration will focus on developing a cervical platform and deploying single-use, sterile-packed procedure solutions designed to increase operating room efficiencies, reduce procedural times and costs, improve patient outcomes through novel device designs and techniques, and reduce infection rates. The partnership includes the co-development of single-use instrumentation for cervical spine procedures. Such instruments are ideal for all surgical settings including acute care hospitals, outpatient hospitals and also ambulatory surgery centers, which are rapidly growing as a preferred site of care for spine procedures. Under the agreement, Orthofix will also exclusively distribute Neo Medical's disruptive value-based thoracolumbar procedure solutions to certain U.S. accounts. Additionally, Orthofix is investing $10M in Neo Medical to support the ongoing partnership, through a combination of a convertible term loan and an equity investment. "We are very excited about the partnership with Neo Medical as we believe it will accelerate our efforts to provide innovative patient-centric procedural solutions that improve outcomes, reduce costs, lower the carbon footprint of reusable instrumentation and increase the applicability of procedures across all surgical settings," said Orthofix President and Chief Executive Officer Jon Serbousek. "We believe there is also a strong value proposition in adapting procedural technology to accommodate the outpatient setting and we have already created initiatives towards optimizing procedural solutions for these facilities."

07:04 EDT Renalytix AI receives California commercial laboratory certification - Renalytix AI announced that it has received a California Clinical Laboratory License from the California Department of Health for its clinical laboratory in Salt Lake City, Utah. KidneyIntelX may now be used to report risk assessment of progressive decline in kidney function for patients in California with early stage diabetic kidney disease. With this certification, the Company is now licensed to provide KidneyIntelX testing services for patients in 49 states. According to the American Society of Nephrology, California has more than five million patients with kidney diseases, 94,000 patients diagnosed with kidney failure and 68,000 patients on dialysis,1 one of the highest rates of CKD in the nation. In August 2020, RenalytixAI announced that it filed a submission seeking clearance of KidneyIntelX with the U.S. Food and Drug Administration. This FDA filing builds on the Company's regulatory and commercialization program, which includes the September 18th announcement of the commercial launch of the KidneyIntelX clinical test reporting platform within the Mount Sinai Health System. This launch follows the announcement that the New York State Department of Health issued a clinical laboratory permit for commercial clinical testing of KidneyIntelX in June 2020.

07:03 EDT Blueprint Medicines announces results from trials of AYVAKIT - Blueprint Medicines announced positive top-line results from the Phase 1 EXPLORER and Phase 2 PATHFINDER clinical trials of AYVAKIT, or avapritinib, in patients with advanced systemic mastocytosis. Consistent with previously reported EXPLORER trial results, the registrational data for AYVAKIT showed profound reductions in mast cell burden, high overall response and complete remission rates, and durable clinical benefit, including prolonged median overall survival, or OS. AYVAKIT was generally well-tolerated, with an improved safety profile at the 200 mg once daily, or QD, dose. Based on these data, Blueprint Medicines plans to submit a supplemental new drug application, or sNDA, to the FDA for AYVAKIT for the treatment of advanced SM in the Q4. SM is a rare, debilitating disease driven by the KIT D816V mutation in nearly all patients.

06:59 EDT AutoZone opened 49 new stores in the U.S in Q4 - During the quarter ended August 29, AutoZone opened 49 new stores in the U.S., 11 stores in Mexico and five stores in Brazil. At the fiscal year end, the company had 5,885 stores in the U.S., 621 stores in Mexico and 43 stores in Brazil for a total count of 6,549.

06:56 EDT AutoZone reports inventory up 3.6% y/y

06:46 EDT Store Capital reports September rent collections of 88% - As of September 21, Store Capital had received rent payments representing 88% of contractual base rent and interest for the month of September. The increase in collections was primarily driven by higher rent collected from tenants in the health club industry. Based on recent payments, the company has now received 87% of both July and August base rent and interest, resulting in aggregate third quarter 2020 cash rent collections of 87%, compared to 73% reported for the second quarter. In addition, according to an updated survey of Store Capital tenants, the percentage of properties open in September also increased to 98% from 93% in August.

06:04 EDT Vubiquity announces partnership with the Liberty Global group - Vubiquity, part of the Amdocs Media Division announced a long-term content services partnership with the Liberty Global group and its affiliates across Europe. The multi-year contract includes the expansion of the existing, long-standing relationship Virgin Media maintains with Vubiquity. Vubiquity will be providing content licensing and digital supply chain solutions to support Liberty Global's consumer video and TV platforms and Virgin Media's on-demand services across cable, broadband and TV.

06:02 EDT Tutor Perini awarded $47M task order - Tutor Perini announced that Black Construction-Tutor Perini JV has been awarded a task order valued at approximately $47M by the Naval Facilities Engineering Command, Pacific Region, for the P-491 Explosive Ordnance Disposal Compound Facilities Project at Naval Base Guam. The project scope of work includes design and construction of a consolidated operations facility, maintenance facility, armory, multipurpose/training facility and certain additional structures. This is the first task order the Company has been awarded under an existing multiple-award construction contract that has a ceiling value of $990M and which is available for additional competitively bid future task order awards through September 2024. The task order value is included in the Company's Q3 backlog. The project is expected to be completed in December 2022.

05:10 EDT Li Auto announces strategic cooperation with Nvidia for Orin SoC chipset - Li Auto (LI) announced a three-way strategic cooperation with Nvidia (NVDA) and Nvidia's Chinese partner, Huizhou Desay SV. Through this strategic cooperation, Li Auto will be the first OEM equipping its vehicles, the full-size extended-range premium smart SUV to be launched in 2022, with the Nvidia Orin SoC chipset. The Nvidia Orin SoC was released in 2019 and is scheduled to be in production in 2022. Orin uses a 7-nanometer production process to achieve a computing power of 200 TOPS, seven times that of the previous generation, the Xavier SoC. Even with the improvement in computing performance, Orin's baseline power consumption is 45 watts. In addition, Li Auto will provide end users with upgradeable solutions, ranging from L2+ autonomous driving with a single Orin chip and 200 TOPS in computing power, to L4 with dual Orin chips and 400 TOPS in computing power. In the future, the use of discrete GPU can further increase the computing power up to 2000 TOPS theoretically, which provides sufficient hardware capabilities for L5 autonomous driving. Desay SV will build on the Orin SoC, and provide an autonomous driving domain controller. On this foundation, Li Auto will develop all autonomous driving program design and algorithms, aiming to become the first new energy vehicle company to independently develop L4 autonomous driving systems in China. Li Auto plans to achieve the full range of autonomous driving in its next generation of vehicles.